Literature DB >> 21153061

Elevated Von Willebrand factor propeptide for the diagnosis of thrombotic microangiopathy and for predicting a poor outcome.

Naomi Ito-Habe1, Hideo Wada, Takeshi Matsumoto, Kohshi Ohishi, Hidemi Toyoda, Eiji Ishikawa, Shinsuke Nomura, Yoshihiro Komada, Masaaki Ito, Tsutomu Nobori, Naoyuki Katayama.   

Abstract

Thrombotic microangiopathy (TMA) is associated with vascular endothelial cell injury and is sometimes linked with poor outcome. Von Willebrand factor (VWF) propeptide (VWFpp) is considered to be a marker of vascular endothelial cell injury. The plasma levels of VWF, VWFpp, and thrombomodulin (TM) were evaluated for their use in the diagnosis of TMA in 75 patients with TMA. There were 30 TMA patients with marked decreases in ADAMTS13 (TMA/ADAMTS13) and 45 without the decrease (TMA/other). The plasma levels of TM, VWF, and VWFpp values were significantly high in patients with TMA, especially TMA/other group. The plasma levels of TM and VWFpp were significantly high in non-survivor with TMA. In the TMA/other group, the plasma levels of VWFpp were negatively correlated with ADAMTS13 activity. The plasma levels of TM correlated with the renal function, but the plasma levels of VWFpp did not. A ROC analysis indicated that VWFpp and TM were useful markers for the prediction of a poor outcome. These findings suggest that VWFpp is an useful marker for the diagnosis of TMA and for the prediction of poor outcome.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21153061     DOI: 10.1007/s12185-010-0732-4

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  22 in total

Review 1.  Thrombotic microangiopathies.

Authors:  Joel L Moake
Journal:  N Engl J Med       Date:  2002-08-22       Impact factor: 91.245

2.  Survival and relapse in patients with thrombotic thrombocytopenic purpura.

Authors:  Johanna A Kremer Hovinga; Sara K Vesely; Deirdra R Terrell; Bernhard Lämmle; James N George
Journal:  Blood       Date:  2009-12-23       Impact factor: 22.113

3.  A second national questionnaire survey of TMA.

Authors:  Naomi Ito-Habe; Hideo Wada; Masanori Matsumoto; Yoshihiro Fujimura; Mitsuru Murata; Takashi Izuno; Minoru Sugita; Yasuo Ikeda
Journal:  Int J Hematol       Date:  2010-06-05       Impact factor: 2.490

4.  Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans.

Authors:  A Borchiellini; K Fijnvandraat; J W ten Cate; D Pajkrt; S J van Deventer; G Pasterkamp; F Meijer-Huizinga; L Zwart-Huinink; J Voorberg; J A van Mourik
Journal:  Blood       Date:  1996-10-15       Impact factor: 22.113

Review 5.  Thrombotic thrombocytopenic purpura: a review.

Authors:  R M Bukowski
Journal:  Prog Hemost Thromb       Date:  1982

Review 6.  Pathogenesis of thrombotic thrombocytopenic purpura: ADAMTS13 deficiency and beyond.

Authors:  Eric Chun-Yet Lian
Journal:  Semin Thromb Hemost       Date:  2005-12       Impact factor: 4.180

7.  Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura.

Authors:  G G Levy; W C Nichols; E C Lian; T Foroud; J N McClintick; B M McGee; A Y Yang; D R Siemieniak; K R Stark; R Gruppo; R Sarode; S B Shurin; V Chandrasekaran; S P Stabler; H Sabio; E E Bouhassira; J D Upshaw; D Ginsburg; H M Tsai
Journal:  Nature       Date:  2001-10-04       Impact factor: 49.962

8.  The Japanese experience with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.

Authors:  Masanori Matsumoto; Hideo Yagi; Hiromichi Ishizashi; Hideo Wada; Yoshihiro Fujimura
Journal:  Semin Hematol       Date:  2004-01       Impact factor: 3.851

9.  Increased levels of vascular endothelial cell markers in thrombotic thrombocytopenic purpura.

Authors:  H Wada; T Kaneko; M Ohiwa; M Tanigawa; T Hayashi; S Tamaki; N Minami; K Deguchi; K Suzuki; T Nakano
Journal:  Am J Hematol       Date:  1993-10       Impact factor: 10.047

10.  Registry of 919 patients with thrombotic microangiopathies across Japan: database of Nara Medical University during 1998-2008.

Authors:  Yoshihiro Fujimura; Masanori Matsumoto
Journal:  Intern Med       Date:  2010-01-01       Impact factor: 1.271

View more
  3 in total

1.  Aging and ABO blood type influence von Willebrand factor and factor VIII levels through interrelated mechanisms.

Authors:  S Albánez; K Ogiwara; A Michels; W Hopman; J Grabell; P James; D Lillicrap
Journal:  J Thromb Haemost       Date:  2016-04-27       Impact factor: 5.824

2.  Atypical hemolytic uremic syndrome: Unique clinical presentation linked to rare CFHR5 mutation.

Authors:  Sofia Menotti; Martino Donini; Giuseppina Pessolano; Livia Tiro; Maurizio Cantini; Jacopo Croce; Matteo Morandi; Filippo Mazzi; Katia Donadello; Oliviero Olivieri; Francesco Dima; Sergio De Marchi; Giovanni Gambaro; Enrico Polati; Lucia De Franceschi
Journal:  EJHaem       Date:  2021-09-14

Review 3.  Differences and similarities between disseminated intravascular coagulation and thrombotic microangiopathy.

Authors:  Hideo Wada; Takeshi Matsumoto; Kei Suzuki; Hiroshi Imai; Naoyuki Katayama; Toshiaki Iba; Masanori Matsumoto
Journal:  Thromb J       Date:  2018-07-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.